WGU D116 – Advanced Pharmacology
Objective Assessment Exam
Why do orally administered drugs with high hepatic extraction ratios often require lower oral doses than
IV doses?
Answer: Because first-pass metabolism inactivates a large fraction of drug before it reaches systemic
circulation.
Rationale: Drugs absorbed from the GI tract pass through the liver via the portal vein before reaching
systemic circulation, so high-extraction drugs lose significant potency orally.
A patient with severe hypoalbuminemia is started on a highly protein-bound medication. What
pharmacokinetic effect should the nurse practitioner anticipate?
Answer: Increased free (unbound) drug concentration and greater risk of toxicity.
Rationale: Fewer binding sites mean more unbound, pharmacologically active drug circulates, raising
toxicity risk even at standard doses.
Explain why a drug with a large volume of distribution is poorly removed by hemodialysis.
Answer: Because most of the drug resides in tissue compartments rather than the plasma, dialysis can
only clear the small plasma fraction.
Rationale: Vd reflects apparent distribution space; a large Vd means the drug is sequestered outside the
vascular compartment where dialysis acts.
How many half-lives are generally required for a drug to reach steady-state concentration?
Answer: Approximately four to five half-lives.
Rationale: Each half-life brings the drug 50% closer to steady state; after four to five half-lives, roughly
94-97% of steady state is reached.
A medication is renally cleared and a patient's creatinine clearance drops significantly. What kinetic
parameter is most directly affected?
Answer: Elimination half-life increases.
Rationale: Reduced clearance without a change in volume of distribution prolongs the half-life, requiring
dose or interval adjustment.
What does zero-order elimination kinetics mean clinically, using phenytoin as an example?
Answer: A constant amount of drug is eliminated per unit time regardless of concentration, so small dose
increases can cause disproportionate rises in serum levels.
Rationale: At high concentrations, phenytoin saturates metabolic enzymes, shifting from first-order to
zero-order kinetics, increasing toxicity risk.
,Why is bioavailability of an IV medication always considered 100%?
Answer: Because the drug is delivered directly into systemic circulation, bypassing absorption barriers
entirely.
Rationale: Bioavailability measures the fraction of administered dose reaching systemic circulation
unchanged; IV administration has no absorption step to reduce this fraction.
A lipophilic drug is administered to an obese patient. How is loading dose calculation typically affected?
Answer: Loading dose is often calculated using total body weight because the drug distributes
extensively into adipose tissue.
Rationale: Lipophilic agents partition into fat, increasing apparent volume of distribution in patients with
higher adipose mass.
Why do neonates generally require lower per-kilogram doses of hepatically metabolized drugs than older
children?
Answer: Because hepatic enzyme systems, particularly CYP450 pathways, are immature at birth.
Rationale: Reduced enzymatic capacity slows metabolism, prolonging half-life and increasing risk of
drug accumulation in neonates.
What is therapeutic drug monitoring used for in narrow therapeutic index medications such as
vancomycin?
Answer: To measure serum drug concentrations and adjust dosing to stay within a safe and effective
range.
Rationale: Narrow therapeutic index drugs have a small margin between therapeutic and toxic
concentrations, so monitoring prevents subtherapeutic dosing and toxicity.
How does gastric pH alteration from a proton pump inhibitor potentially affect absorption of
ketoconazole?
Answer: It can reduce ketoconazole absorption because the drug requires an acidic environment for
dissolution.
Rationale: Weakly basic drugs like ketoconazole depend on gastric acidity for adequate dissolution and
absorption; acid-suppressing agents can blunt bioavailability.
Define enterohepatic recirculation and its clinical significance.
Answer: It is the process by which a drug excreted in bile is reabsorbed from the intestine back into
circulation, prolonging its duration of action.
Rationale: This recycling can extend a drug's effect and half-life, and interruption of the cycle can be
used therapeutically, such as with bile acid sequestrants.
,Why might a drug interaction that inhibits CYP3A4 lead to toxicity of a co-administered statin?
Answer: Because reduced metabolism increases plasma statin concentrations, raising the risk of
myopathy or rhabdomyolysis.
Rationale: Many statins are CYP3A4 substrates; enzyme inhibition slows their clearance, allowing
accumulation to toxic levels.
What is the clinical relevance of a drug's therapeutic index?
Answer: It describes the margin between an effective dose and a toxic dose, guiding how closely a
medication must be monitored.
Rationale: A narrow therapeutic index requires careful dosing and monitoring, while a wide index allows
more dosing flexibility.
How does renal impairment affect dosing of a drug that is primarily eliminated unchanged by the
kidneys?
Answer: Dose or dosing interval typically must be reduced to prevent accumulation and toxicity.
Rationale: Decreased glomerular filtration slows elimination, so standard dosing in renal impairment can
result in supratherapeutic drug levels.
Why is loading dose independent of a patient's renal or hepatic clearance, while maintenance dose is not?
Answer: Because loading dose depends on volume of distribution to achieve a target concentration
quickly, whereas maintenance dose depends on clearance to sustain that concentration.
Rationale: Vd determines how much drug is needed to fill the distribution space; clearance determines
how much must be replaced over time.
Distinguish between a full agonist and a partial agonist at the same receptor.
Answer: A full agonist produces the maximum possible response, while a partial agonist produces a
submaximal response even at full receptor occupancy.
Rationale: Partial agonists have lower intrinsic efficacy, which is why they can act as agonists alone but
as functional antagonists when combined with a full agonist.
Why can buprenorphine precipitate withdrawal in a patient physically dependent on full opioid agonists?
Answer: Because buprenorphine has high receptor affinity but only partial intrinsic activity, displacing
full agonists and reducing net receptor stimulation.
Rationale: Its partial agonist activity lowers overall opioid effect at the receptor compared to the full
agonist it displaces, triggering withdrawal symptoms.
What is the difference between drug potency and drug efficacy?
Answer: Potency refers to the dose required to produce a given effect, while efficacy refers to the
maximum effect a drug can produce.
, Rationale: A more potent drug requires a smaller dose, but potency does not indicate how large the
maximal therapeutic effect will be.
Explain competitive antagonism using naloxone as an example.
Answer: Naloxone binds reversibly to opioid receptors and can be displaced by increasing agonist
concentration, though clinically it is used to displace opioids and reverse effects.
Rationale: Competitive antagonists compete for the same binding site, and the antagonism can
theoretically be overcome by sufficiently high agonist concentrations.
How does a noncompetitive antagonist differ from a competitive antagonist in its effect on the
dose-response curve?
Answer: A noncompetitive antagonist reduces the maximum achievable effect, while a competitive
antagonist shifts the curve rightward without lowering the maximum.
Rationale: Noncompetitive antagonism often involves irreversible binding or allosteric modulation that
cannot be overcome by increasing agonist dose.
Why do patients on long-term beta-agonist therapy sometimes experience reduced bronchodilator
response over time?
Answer: Receptor downregulation and desensitization can occur with chronic agonist exposure, reducing
drug effect.
Rationale: Sustained receptor stimulation triggers internalization and reduced receptor density, a
phenomenon known as tachyphylaxis or tolerance.
What does a steep dose-response curve imply about the safety margin of a medication?
Answer: A steep curve suggests a small dose change can cause a large change in effect, narrowing the
margin for safe titration.
Rationale: Medications with steep dose-response relationships require more cautious, incremental
titration to avoid overshooting the desired therapeutic effect.
Define the concept of receptor spare capacity and its clinical implication.
Answer: It refers to a situation where maximal response can be achieved without occupying all available
receptors, allowing lower doses to still produce full effect.
Rationale: When spare receptors exist, submaximal receptor occupancy is sufficient for maximal
response, which can influence dosing strategy.
How does an inverse agonist differ from a neutral antagonist?
Answer: An inverse agonist actively reduces receptor activity below baseline, while a neutral antagonist
blocks agonist binding without altering baseline activity.
Objective Assessment Exam
Why do orally administered drugs with high hepatic extraction ratios often require lower oral doses than
IV doses?
Answer: Because first-pass metabolism inactivates a large fraction of drug before it reaches systemic
circulation.
Rationale: Drugs absorbed from the GI tract pass through the liver via the portal vein before reaching
systemic circulation, so high-extraction drugs lose significant potency orally.
A patient with severe hypoalbuminemia is started on a highly protein-bound medication. What
pharmacokinetic effect should the nurse practitioner anticipate?
Answer: Increased free (unbound) drug concentration and greater risk of toxicity.
Rationale: Fewer binding sites mean more unbound, pharmacologically active drug circulates, raising
toxicity risk even at standard doses.
Explain why a drug with a large volume of distribution is poorly removed by hemodialysis.
Answer: Because most of the drug resides in tissue compartments rather than the plasma, dialysis can
only clear the small plasma fraction.
Rationale: Vd reflects apparent distribution space; a large Vd means the drug is sequestered outside the
vascular compartment where dialysis acts.
How many half-lives are generally required for a drug to reach steady-state concentration?
Answer: Approximately four to five half-lives.
Rationale: Each half-life brings the drug 50% closer to steady state; after four to five half-lives, roughly
94-97% of steady state is reached.
A medication is renally cleared and a patient's creatinine clearance drops significantly. What kinetic
parameter is most directly affected?
Answer: Elimination half-life increases.
Rationale: Reduced clearance without a change in volume of distribution prolongs the half-life, requiring
dose or interval adjustment.
What does zero-order elimination kinetics mean clinically, using phenytoin as an example?
Answer: A constant amount of drug is eliminated per unit time regardless of concentration, so small dose
increases can cause disproportionate rises in serum levels.
Rationale: At high concentrations, phenytoin saturates metabolic enzymes, shifting from first-order to
zero-order kinetics, increasing toxicity risk.
,Why is bioavailability of an IV medication always considered 100%?
Answer: Because the drug is delivered directly into systemic circulation, bypassing absorption barriers
entirely.
Rationale: Bioavailability measures the fraction of administered dose reaching systemic circulation
unchanged; IV administration has no absorption step to reduce this fraction.
A lipophilic drug is administered to an obese patient. How is loading dose calculation typically affected?
Answer: Loading dose is often calculated using total body weight because the drug distributes
extensively into adipose tissue.
Rationale: Lipophilic agents partition into fat, increasing apparent volume of distribution in patients with
higher adipose mass.
Why do neonates generally require lower per-kilogram doses of hepatically metabolized drugs than older
children?
Answer: Because hepatic enzyme systems, particularly CYP450 pathways, are immature at birth.
Rationale: Reduced enzymatic capacity slows metabolism, prolonging half-life and increasing risk of
drug accumulation in neonates.
What is therapeutic drug monitoring used for in narrow therapeutic index medications such as
vancomycin?
Answer: To measure serum drug concentrations and adjust dosing to stay within a safe and effective
range.
Rationale: Narrow therapeutic index drugs have a small margin between therapeutic and toxic
concentrations, so monitoring prevents subtherapeutic dosing and toxicity.
How does gastric pH alteration from a proton pump inhibitor potentially affect absorption of
ketoconazole?
Answer: It can reduce ketoconazole absorption because the drug requires an acidic environment for
dissolution.
Rationale: Weakly basic drugs like ketoconazole depend on gastric acidity for adequate dissolution and
absorption; acid-suppressing agents can blunt bioavailability.
Define enterohepatic recirculation and its clinical significance.
Answer: It is the process by which a drug excreted in bile is reabsorbed from the intestine back into
circulation, prolonging its duration of action.
Rationale: This recycling can extend a drug's effect and half-life, and interruption of the cycle can be
used therapeutically, such as with bile acid sequestrants.
,Why might a drug interaction that inhibits CYP3A4 lead to toxicity of a co-administered statin?
Answer: Because reduced metabolism increases plasma statin concentrations, raising the risk of
myopathy or rhabdomyolysis.
Rationale: Many statins are CYP3A4 substrates; enzyme inhibition slows their clearance, allowing
accumulation to toxic levels.
What is the clinical relevance of a drug's therapeutic index?
Answer: It describes the margin between an effective dose and a toxic dose, guiding how closely a
medication must be monitored.
Rationale: A narrow therapeutic index requires careful dosing and monitoring, while a wide index allows
more dosing flexibility.
How does renal impairment affect dosing of a drug that is primarily eliminated unchanged by the
kidneys?
Answer: Dose or dosing interval typically must be reduced to prevent accumulation and toxicity.
Rationale: Decreased glomerular filtration slows elimination, so standard dosing in renal impairment can
result in supratherapeutic drug levels.
Why is loading dose independent of a patient's renal or hepatic clearance, while maintenance dose is not?
Answer: Because loading dose depends on volume of distribution to achieve a target concentration
quickly, whereas maintenance dose depends on clearance to sustain that concentration.
Rationale: Vd determines how much drug is needed to fill the distribution space; clearance determines
how much must be replaced over time.
Distinguish between a full agonist and a partial agonist at the same receptor.
Answer: A full agonist produces the maximum possible response, while a partial agonist produces a
submaximal response even at full receptor occupancy.
Rationale: Partial agonists have lower intrinsic efficacy, which is why they can act as agonists alone but
as functional antagonists when combined with a full agonist.
Why can buprenorphine precipitate withdrawal in a patient physically dependent on full opioid agonists?
Answer: Because buprenorphine has high receptor affinity but only partial intrinsic activity, displacing
full agonists and reducing net receptor stimulation.
Rationale: Its partial agonist activity lowers overall opioid effect at the receptor compared to the full
agonist it displaces, triggering withdrawal symptoms.
What is the difference between drug potency and drug efficacy?
Answer: Potency refers to the dose required to produce a given effect, while efficacy refers to the
maximum effect a drug can produce.
, Rationale: A more potent drug requires a smaller dose, but potency does not indicate how large the
maximal therapeutic effect will be.
Explain competitive antagonism using naloxone as an example.
Answer: Naloxone binds reversibly to opioid receptors and can be displaced by increasing agonist
concentration, though clinically it is used to displace opioids and reverse effects.
Rationale: Competitive antagonists compete for the same binding site, and the antagonism can
theoretically be overcome by sufficiently high agonist concentrations.
How does a noncompetitive antagonist differ from a competitive antagonist in its effect on the
dose-response curve?
Answer: A noncompetitive antagonist reduces the maximum achievable effect, while a competitive
antagonist shifts the curve rightward without lowering the maximum.
Rationale: Noncompetitive antagonism often involves irreversible binding or allosteric modulation that
cannot be overcome by increasing agonist dose.
Why do patients on long-term beta-agonist therapy sometimes experience reduced bronchodilator
response over time?
Answer: Receptor downregulation and desensitization can occur with chronic agonist exposure, reducing
drug effect.
Rationale: Sustained receptor stimulation triggers internalization and reduced receptor density, a
phenomenon known as tachyphylaxis or tolerance.
What does a steep dose-response curve imply about the safety margin of a medication?
Answer: A steep curve suggests a small dose change can cause a large change in effect, narrowing the
margin for safe titration.
Rationale: Medications with steep dose-response relationships require more cautious, incremental
titration to avoid overshooting the desired therapeutic effect.
Define the concept of receptor spare capacity and its clinical implication.
Answer: It refers to a situation where maximal response can be achieved without occupying all available
receptors, allowing lower doses to still produce full effect.
Rationale: When spare receptors exist, submaximal receptor occupancy is sufficient for maximal
response, which can influence dosing strategy.
How does an inverse agonist differ from a neutral antagonist?
Answer: An inverse agonist actively reduces receptor activity below baseline, while a neutral antagonist
blocks agonist binding without altering baseline activity.
